Related Experiment Videos
Application of antisense technology to therapeutics
O Heidenreich1, S H Kang, X Xu
1Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037, USA.
Molecular Medicine Today
|June 1, 1995
Summary
Antisense oligonucleotides (ASOs) are promising for treating diseases by blocking gene expression. However, challenges like delivery, toxicity, and off-target effects hinder their widespread clinical use.
Area of Science:
- Molecular Biology
- Medicinal Chemistry
- Pharmacology
Background:
- Antisense oligonucleotides (ASOs) are short nucleic acid sequences designed to inhibit gene expression.
- Chemical modifications enhance ASO stability against nuclease degradation, improving their therapeutic potential.
- ASOs are being investigated for antiviral and anticancer applications.
Purpose of the Study:
- To review current applications of antisense oligonucleotides in medicine.
- To discuss the significant challenges limiting the clinical use of ASOs.
Main Methods:
- Review of existing literature on antisense oligonucleotide applications.
- Analysis of challenges including cellular delivery, tissue toxicity, and off-target effects.
Main Results:
- ASOs demonstrate potential in targeting specific RNA molecules to modulate gene expression.
- Chemically modified ASOs exhibit increased resistance to degradation.
- Significant hurdles remain in achieving efficient and safe therapeutic delivery.
Conclusions:
- Antisense oligonucleotide technology holds promise for novel therapeutic strategies.
- Overcoming limitations in delivery, toxicity, and off-target effects is crucial for ASO clinical translation.
- Further research is needed to optimize ASO design and application for human diseases.